The US FDA has accepted the resubmission of a new drug application for what would be the first digital medicine, which combines Otsuka Pharmaceutical’s antipsychotic agent Abilify (aripiprazole) with an embedded ingestible sensor developed by Proteus Digital Health, the two…
To read the full story
Related Article
- FDA Approves Sensor-Embedded Abilify, World’s 1st Digital Pill
November 15, 2017
- Otsuka Aims to Resubmit NDA for Sensor-Embedded Abilify in US by Mid-Year
February 14, 2017
BUSINESS
- Ultragenyx Seeks Japan Approval for GSDIa Gene Therapy
July 1, 2026
- Specialist Hails Wegovy as “Game Changer” for MASH Treatment
July 1, 2026
- Alfresa Boosts Stake in ENT Cell Sheet Startup
July 1, 2026
- Eisai, UCL Renew Neuroscience Alliance to 2030
July 1, 2026
- Asahi Kasei Nabs Japan Rights to Additional Empaveli Indications
July 1, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





